From Shennong to digitizing drug research and development, for thousands of years, the pharmaceutical industry has always stood in the front line in the fight against diseases and epidemics, and helped mankind win victory again and again through innovation and breakthroughs. As China enters an aging society, the sharply increased demand for drugs has further promoted the development of the drug market, and China's pharmaceutical industry is rapidly moving in the direction of high quality, entering a critical period of transformation from a "pharmaceutical power" to a "pharmaceutical power".
In promoting the construction of new industrialization, the dual transformation of digitalization and green low-carbon has become the only way for the pharmaceutical industry to achieve high-quality development, and cutting-edge emerging technologies such as digital twin, artificial intelligence, cloud edge collaboration, big data, and carbon reduction have also brought unlimited possibilities for the development of the pharmaceutical industry. The "14th Five-Year Plan" for the development of the pharmaceutical industry clearly puts forward the goals of green, digital and intelligent development of enterprises, in order to promote the upgrading of the pharmaceutical manufacturing capacity system, continuously improve the quality and safety level, promote the digital transformation of the industry, promote the green and low-carbon development of the whole industrial chain and improve the ability to control security risks.
According to statistics, among the 153 factories in the global lighthouse network, there are 22 in the pharmaceutical industry, and there are more than 40 lighthouse factories, but China's local pharmaceutical companies are still blank. Whether it is a newly emerging biopharmaceutical in recent years, or a mature chemical pharmaceutical with the largest volume in the pharmaceutical industry, there is an urgent need to improve efficiency and win the competitiveness of the industry through digital transformation.
From biopharmaceuticals to chemical pharmaceuticals, green "smart" drugs are accelerating
Biopharmaceutical is a kind of pharmaceutical method which makes use of the principles and methods of microbiology, chemistry, biotechnology and pharmacy. In the pharmaceutical industry, the structure and process of biological drugs are the most complex, and the safety evaluation requirements are also more challenging. Its production chain covers material management, raw liquid process, preparation process, packaging process, warehousing and logistics and other links, subject to personnel operation, equipment interaction, material weighing and production standards, often in the actual management of production management at all levels is difficult to cooperate, human error is difficult to avoid, heavy workload of material weighing and a series of problems. It greatly increases the difficulty of risk control of the whole process.
The chemical pharmaceutical industry includes chemical raw materials and chemical preparations, and its raw materials rely on the subdivisions of the chemical industry - the basic chemical industry and the fine chemical industry. Chemical pharmacy emphasizes precise steps so that each chemical reaction is fully controlled. Taking the raw material process as an example, the raw material belongs to fine chemical pharmaceutical, which not only has fixed tube and tank process design, high energy consumption and low efficiency in the production process, but also involves a dangerous process, and core control, cost reduction and efficiency improvement and safe production are its core demands.
Drug safety is a matter of life, and the pharmaceutical industry has always been a highly regulated industry. With the landing of the new medical reform policy, GMP (drug production management practice) certification has become a normal supervision, drug consistency evaluation has become a mandatory requirement of the industry, from biopharmaceutical to chemical pharmaceutical, are facing multiple challenges such as quality, compliance, safety, stability, efficiency and so on.
A seven-step approach to digital transformation empowers the pharmaceutical industry to enhance the four major values
As an expert in digital transformation in the field of global energy management and automation, Schneider Electric has innovated the "seven-step method" of digital transformation from project stage to operation stage with its rich technical reserves and industry practical experience, helping enterprises to carry out efficient management and control of the whole life cycle, and bringing four values of lean and efficient, safety and compliance, openness and transparency, and sustainable development to enterprises. Accelerate digital transformation and achieve sustainable development.
• Schneider Electric Digital Transformation Consulting Services: Covering strategic, operational and technical level consulting, it can help pharmaceutical companies to carry out top-level strategic planning such as lean production, supply chain collaboration, production optimization, smart factory planning, and formulate more in-depth and refined digital transformation strategies, determine digital objectives and implementation plans, evaluate digital priorities and feasibility, and then comprehensively empower organizations to improve corporate efficiency. Achieve better transformation results.
email:1583694102@qq.com
wang@kongjiangauto.com